Quality Management in Pharma: Johnson & Johnson vs. Mylan
This paper compares the quality management processes of two pharmaceutical companies — Johnson & Johnson, a global industry leader, and Mylan, a domestic generic drug producer. Focusing on traceability as a core quality management function, the analysis examines how each company's supply chain strategies, supplier auditing practices, and regulatory compliance frameworks differ based on their respective business models. The paper also explores how traceability contributes to competitive advantage and brand reputation, and argues that quality management is not merely a compliance requirement but a strategic priority for both global and domestic pharmaceutical manufacturers.
- Introduction: Overview of two firms and analytical framework
- Traceability Processes at Johnson & Johnson and Mylan: Operational traceability differences including RFID and audits
- How Traceability Contributes to Greater Competitiveness: Traceability as strategic and competitive advantage
- Quality Management and Market Position: Brand value and reputation tied to quality systems
- Conclusion: Strategic importance of pharmaceutical quality management
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Uses a concrete side-by-side comparison of two real companies to ground abstract quality management concepts in industry practice.
- Connects operational details (RFID adoption, Six Sigma, supplier audits) to broader strategic outcomes like brand reputation and competitive positioning.
- Anchors claims with peer-reviewed citations from supply chain and health care quality journals, lending credibility to the analysis.
Key academic technique demonstrated
The paper demonstrates comparative analysis as a structured academic technique: it establishes a shared framework (traceability) and then systematically applies it to two organizations with different business models, scale, and strategic priorities. This approach allows the author to highlight meaningful differences rather than simply listing facts about each company in isolation.
Structure breakdown
The paper opens with an introduction that identifies both companies and the analytical lens (traceability and quality management). A dedicated traceability section — supported by a referenced workflow diagram — examines operational differences, including RFID adoption and supplier auditing depth. A subsequent section elevates the discussion to competitive strategy, arguing that traceability is more than compliance. The final substantive section ties quality management directly to brand value and market position for each firm, before a brief closing argument.
Introduction
Comparing the quality management processes of global and domestic pharmaceutical organizations yields significantly different results. The two companies included in this analysis are Johnson & Johnson, a global leader in the pharmaceutical industry, and Mylan, a domestic producer of generic drugs. Supplier quality management strategies at each company follow a comparable framework that includes reverse logistics, which enables traceability (Kumar, Dieveney, & Dieveney, 2009). Both companies are also continually evaluated by the Food & Drug Administration, which has the authority of the federal government to launch on-site audits, unannounced, any day of the year (Murray & McAdam, 2007). Quality management and compliance are critical for risk reduction — not just from a governance standpoint but from an operating expense reduction standpoint as well (Fiscus, 2009). The process of traceability, which is critical for quality management and compliance, is compared between these two firms.
Traceability Processes at Johnson & Johnson and Mylan
A process-based analysis of traceability maps the functional areas of an organization as rows, with the traceability process defined by specific steps. This workflow illustrates how collaborative and integrated the entire traceability process is within a pharmaceutical producer. This level of integration is critical from a process standpoint, as government-defined quality standards require traceability throughout any pharmaceutical organization's supply chain (Murray & McAdam, 2007).
These process steps vary in terms of their depth and global scalability between the two companies included in this analysis. For Johnson & Johnson, the need to manage global traceability and recalls is critical. As a result, their distributed supply chain management systems and manufacturing centers have upstream traceability procedures defined, while Mylan does not. Upstream traceability is not necessary for Mylan, as they are a generic drug manufacturer that relies on a direct sales force. Johnson & Johnson has also automated the supplier batch traceability function and is piloting the use of Radio Frequency Identification (RFID) to more efficiently manage their supply chains (Hook, 2010). Mylan is not planning to adopt RFID for warehouse management and is instead concentrating on regulatory compliance and reverse logistics. Mylan is also defining supplier quality management performance metrics and has invested heavily in supplier audits and Six Sigma quality management.
Mylan regards itself as a process goods producer in the pharmaceutical industry, while Johnson & Johnson has a more diverse portfolio of products and divisions, with 57% of total revenues in the last fiscal year coming from pharmaceuticals. Due to this difference in business models, raw materials and components supplier auditing — a key functional area of the traceability process — is far more diverse at Johnson & Johnson and requires even greater auditing depth than the comparable process at Mylan. Johnson & Johnson must also be highly vigilant about how quality impacts its corporate and product brands, while Mylan is often sold as a generic drug through distribution outlets including grocery and mass merchandiser chains. Quality as a product differentiator must be an explicit goal in defining audit objectives in highly regulated industries if manufacturers are to retain and grow the trust of their suppliers and distribution channels (Schnoll, 2008).
How Traceability Contributes to Greater Competitiveness
Traceability is essential for both companies to remain in compliance with domestic and global pharmaceutical standards and laws, yet this is just the baseline from which both companies begin. For traceability to effectively contribute to greater competitiveness, the process must be viewed as continuously improving. The tangential processes related to traceability — from reverse logistics and supply chain management to pricing and brand management — all have a major impact on each company's ability to maintain its pricing structure and business model. In effect, this process is pivotal to each company attaining its strategic goals.
Traceability also connotes accountability and responsibility, both of which are critical when a bad lot of ingredients is delivered. In the unfortunate event of such an occurrence, the speed of response in tracking the source of the materials and isolating which products and distributors are affected is critical. Companies that cannot answer these tough questions quickly during a product recall face serious damage to their reputations and the trust they have built with customers and partners.
Conclusion
Both Johnson & Johnson and Mylan demonstrate that quality management is not merely a compliance obligation but a strategic imperative. Whether a company operates as a global pharmaceutical leader or a domestic generic drug producer, robust traceability, supplier auditing, and continuous process improvement are foundational to competitive positioning, brand integrity, and the protection of public health. In the pharmaceutical industry, quality management deserves significant strategic attention in organizations serving the public with medications.
References
Connolly, C. (2007). Sensor trends in processing and packaging of foods and pharmaceuticals. Sensor Review, 27(2), 103.
Enderwick, P. (2009). Avoiding quality fade in Chinese global supply chains: Designing appropriate governance structures. Business Process Management Journal, 15(6), 876–894.
Fiscus, P. (2009). Global risks for drug manufacturers. Risk Management, 56(3), 50–54.
Hook, B. (2010, March). Traceability and scalability: A new era in healthcare logistics. Supply Chain Europe, 19(2), 18–19.
Kumar, S., Dieveney, E., & Dieveney, A. (2009). Reverse logistic process control measures for the pharmaceutical industry supply chain. International Journal of Productivity and Performance Management, 58(2), 188–204.
Murray, E., & McAdam, R. (2007). A comparative analysis of quality management standards for contract research organisations in clinical trials. International Journal of Health Care Quality Assurance, 20(1), 16–33.
Schnoll, L. (2008). Ensuring supplier quality. Quality Progress, 41(8), 64–66.
Create your account
Always verify citation format against your institution’s current style guide requirements.